Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
EKSO 
Ekso Bionics Holdings Inc (EKSO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: EKSO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.84% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.42M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 295734 | Beta 1.43 | 52 Weeks Range 0.34 - 1.53 | Updated Date 03/31/2025 |
52 Weeks Range 0.34 - 1.53 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.08 | Actual -0.14 |
Profitability
Profit Margin -63.21% | Operating Margin (TTM) -43.81% |
Management Effectiveness
Return on Assets (TTM) -23.53% | Return on Equity (TTM) -89.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9906470 | Price to Sales(TTM) 0.56 |
Enterprise Value 9906470 | Price to Sales(TTM) 0.56 | ||
Enterprise Value to Revenue 0.55 | Enterprise Value to EBITDA 0.46 | Shares Outstanding 24824800 | Shares Floating 21108743 |
Shares Outstanding 24824800 | Shares Floating 21108743 | ||
Percent Insiders 7.01 | Percent Institutions 16.31 |
Analyst Ratings
Rating 4.5 | Target Price 5.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ekso Bionics Holdings Inc
Company Overview
History and Background
Ekso Bionics Holdings Inc. was founded in 2005. It designs, develops, and markets exoskeletons to augment human strength and endurance. Initially focused on military applications, the company transitioned to medical and industrial markets. A significant milestone was FDA clearance for its EksoGT exoskeleton in 2016.
Core Business Areas
- Medical: Development and sale of exoskeletons for rehabilitation and assistive purposes in clinical settings. Primarily for stroke and spinal cord injury patients.
- Industrial: Development and sale of exoskeletons to reduce strain and fatigue in industrial workers.
Leadership and Structure
The CEO is Steven Sherman. The company has a board of directors and operates with functional departments including R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- EksoNR: An exoskeleton used in rehabilitation centers for stroke and spinal cord injury patients. Market share data is difficult to pinpoint precisely, but Ekso Bionics is a leading player in the rehabilitation exoskeleton market. Competitors include ReWalk Robotics (RWLK) and Cyberdyne.
- EksoVest: An upper-body exoskeleton designed to reduce fatigue and injury risk for industrial workers performing overhead tasks. Again market share data is not readily available, but Ekso competes with companies like Levitate Technologies and Ottobock.
Market Dynamics
Industry Overview
The exoskeleton market is growing, driven by increasing demand for rehabilitation solutions, improved workplace safety, and advancements in robotics and sensor technology. The medical segment is heavily regulated and focused on clinical efficacy while the industrial sector focuses on ergonomics and cost savings.
Positioning
Ekso Bionics is a key player in the exoskeleton market, particularly in medical rehabilitation. Its competitive advantages include established technology, FDA clearance for specific products, and partnerships with rehabilitation centers and industrial companies.
Total Addressable Market (TAM)
The exoskeleton market is projected to reach billions of dollars in the next decade. Ekso Bionics is positioned to capture a share of this market, particularly in the medical and industrial sectors. The TAM is estimated to be between $1B-$3B.
Upturn SWOT Analysis
Strengths
- FDA clearance for EksoGT
- Established brand recognition in the medical exoskeleton market
- Strong intellectual property portfolio
- Partnerships with leading rehabilitation centers
Weaknesses
- High product cost
- Limited market penetration in the industrial sector
- Reliance on third-party reimbursement for medical devices
- History of net losses
Opportunities
- Expanding applications in military and construction
- Developing more affordable exoskeleton solutions
- Increasing awareness of workplace safety and ergonomics
- Growing demand for rehabilitation services
Threats
- Competition from established medical device companies
- Regulatory hurdles and reimbursement challenges
- Technological advancements leading to obsolescence
- Economic downturn affecting healthcare and industrial spending
Competitors and Market Share
Key Competitors
- RWLK
- CYBRF
Competitive Landscape
Ekso Bionics faces competition from established medical device companies and specialized exoskeleton manufacturers. Ekso's advantages lie in its FDA clearance and brand recognition, while its disadvantages include high product cost and limited market penetration in some areas.
Major Acquisitions
MediTouch
- Year: 2016
- Acquisition Price (USD millions): 7.2
- Strategic Rationale: Expanded Ekso's product portfolio into functional electrical stimulation (FES) and other rehabilitation technologies.
Growth Trajectory and Initiatives
Historical Growth: Ekso Bionics has demonstrated growth in revenue, but profitability has been a challenge. The company has expanded its product portfolio and market presence.
Future Projections: Analysts expect continued revenue growth, driven by increasing adoption of exoskeletons in medical and industrial markets. Profitability is expected to improve but remains uncertain.
Recent Initiatives: Recent initiatives include strategic partnerships with industrial companies, product development efforts focused on affordability, and market expansion into new geographies.
Summary
Ekso Bionics is a key player in the exoskeleton market, especially in the medical rehabilitation sector with its FDA-cleared products. Its high product costs, history of losses, and reliance on external funding pose challenges. Opportunities exist in expanding industrial applications and developing more affordable solutions. They need to watch for regulatory hurdles, competition, and technological obsolescence.
Similar Companies
- RWLK
- INOD
- VAREX
- HOLX
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is based on available information and estimates, and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ekso Bionics Holdings Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 2014-01-16 | CEO & Director Mr. Scott G. Davis | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 61 | Website https://www.eksobionics.com |
Full time employees 61 | Website https://www.eksobionics.com | ||
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.